Analyses of the phase 3 CheckMate649 trial show that in patients with gastroesophageal cancer, KRAS alterations were associated with greater overall survival when treated with nivolumab plus chemotherapy vs chemotherapy alone. @yjanjigianMD Kohei shitara nature.com/articles/s4159…

Exciting to annouce, Young ISDE ISDE.net Afrin Kamal MD, MS Jessie Elliott has activated a database for international fellowships in esophageal diseases - for surg, gastro, scientist, allied health etc. Please enter your centre's data and spread the word. isde.net/fellowship-opp…

Hot off the press! "International Society for Diseases of the Esophagus consensus on management of the failed fundoplication" #GERD #SoMe4Surgery #ISDE #EsophagealSurgery ow.ly/qWpL50Vr3wj

What is the optimal length of POEM for achalasia? "Standard length of peroral endoscopic myotomy (POEM) for achalasia: a systematic review and meta-analysis" ow.ly/fmLZ50Vr3x9

🚨DYNAMIC-III🚨 🔎R0 resected stage 3 colon cancer, post-op ctDNA + Randomized SoC vs intensified Systemic therapy ⛔️No improvement in RFS with intensification 🧐While ctDNA+ is prognostic, work is needed to identify how tx/selection may be altered to ⬆️outcomes #ASCO25

I disagree with the statement that nivo demonstrated OS survival improvement in Checkmate577, when the CI overlaps 1! I agree nivo is a clinically useful agent after CRT, especially for esoph SCC. While an ⬆️ OS is plausible, the data presented do not prove it.

First trial of CAR-T cell ca tx for solid tumor response: ASCO #ASCO25 Satricabtagene autoleucel (satri-cel)/CT041 demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit in patients with previously treated,

#ASCO25 OG orals take homes: 1. CM577: adj nivo SCC only 🚫 mixed histology trials! 2. LEAP15: chemo+TKI+ICI=too much 🔎 Attention to the safety run-in 3. DG04: TDXD 1.1m PFS 3.3m OS ⬆️ 💉biopsy after 1L 4. CLD 18.2 CAR-T: 4m PFS 🔬 More work needed on tox vs efficacy

Matterhorn is out! Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

🚨 1 Week Left! Early bird registration for #ISDE2025 closes June 12! Join global experts in esophageal health Sept 18–20 in Brisbane 🇦🇺 ✅ Save up to $100 ✅ Top hotels still available ✅ Cutting-edge science & networking isde-congress.net/registration/ #ISDE #esophagus #esophageal

🌆 Don’t miss the #ISDE2025 Congress Dinner on Sept 19! Dine above #Brisbane at the Sky Room with iconic views, Aussie flavors, live entertainment & great company. 📍 BCEC 🕖 7–10PM 👔 Biz casual 💵 $165 USD Secure your spot now👉isde-congress.net/registration/ #esophagus #esophageal

Posted this now bioRxiv ! A comprehensive effort from McGill University detailing progressive refinement of gastroesophageal adenocarcinoma patient-derived #organoid generation. A huge bio repository of almost 400 patient tumours! Organoid News biorxiv.org/content/10.110…

CALLLING all Allied Health and Nurses interested in Upper GI diseases. We are offering 2 bursaries to support any Allied Health and Nurses attend the AANZGOSA ASM, on 17 Sept, Brisbane. Visit: aanzgosa-asm.com/travel-bursary/ Early bird: ends 14th August See you in Brisbane! AANZGOSA

Effects of postoperative complications in oesophageal cancer on survival, hospital outcomes, and long-term quality of life: retrospective cohort study ➡️doi.org/10.1093/bjsope… This study evaluated the impact of postoperative complications on long-term survival and recurrence in

Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... sciencedirect.com/science/articl… Led by very talented Joseph J Zhao and Kennedy Ng. Raghav Sundar

Only 4 days to the end of EARLY BIRD Registrations for this year's jam packed AANZGOSA Conference, Brisbane, 17th Sept. Just before ISDE.net 2 birds, 1 stone: Come to both! Get online now and register: aanzgosa-asm.com/event-registra… isde-congress.net

Lorenzo Ferri, ISDS President: Our strength as a society comes from sharing our expertise and learning from one another. I encourage every one of you to submit your work, be part of the conversation, and help shape the future of our specialty. 🔗buff.ly/EwtAPxA

Final OS analysis of KN585 published in Journal of Clinical Oncology ASCO. OS HR has been changed from 0.90 at primary The Lancet Oncology to 0.86. HR in FLOT cohort also shifted from 1.02 to 0.81. Hoping MATTERHORN OS HR will also further improve with longer follow-up. ascopubs.org/doi/10.1200/JC…

We are "crowd-sourcing" an International Fellowships Database for esophageal surgery, medicine and research. If your team offers fellowship opportunities, we invite you to join a global platform that brings together institutions from around the world! ➡️ isde.net/fellowship-opp…

Wonderful opening session of the AANZGOSA 2025 conference in Brisbane today - running in parallel with #ISDE2025 ISDE.net 🇦🇺🌏